Label-Free Cellular Profiling Service for Drug Discovery

Corning Inc have announced its new Corning® Epic® Pharmacology service for drug discovery. The service uses Corning’s holistic assay approach to drug discovery and pathway biology to provide high-value cellular profiling
in native cellular systems.

The Corning Epic Pharmacology service is a key new offering from Corning’s portfolio of Epic Discovery Services, and helps reveal hidden compound activities, unforeseen pathway activities, and can identify both novel pharmacology and off-target effects for highvalue compounds.

Leveraging Corning’s innovative Epic label-free technology, the Epic Pharmacology service provides more biologically relevant data to enhance customers’ decision-making in compound prioritisation, helping them drive increased discovery productivity.

“Today’s drug discovery market is challenged not only with bringing drugs to market faster, but doing so more efficiently and effectively while remaining continually vigilant about quality,” said Keith R. Olson, PhD, Business
Director, Advanced Life Sciences, Corning.

“Our new Corning Epic Pharmacology service will provide our customers worldwide with significant knowledge and expertise needed to address and overcome these current challenges. Our approach is customised to each client’s need, providing a cellular profiling panel for drug activity in a range of primary and immortalised cells that more accurately reflects how drugs behave in vivo.”

Corning is highlighted its Corning Epic Pharmacology service at the inaugural SLAS 2012 event, 4-8 February in San Diego. An exhibitor at the event, Corning i also presented technical posters and hosting a number of workshops to demonstrate applications for Corning Epic technology and the new pharmacology service.